TITLE: Viraemia and HIV drug resistance among people receiving dolutegravir versus efavirenz-based first-line antiretroviral therapy

Authors: Jienchi Dorward¹,², Yukteshwar Sookrajh³, Richard Lessells²⁴, Elliot Bullo³, Nicola Bodley², Lavanya Singh⁴, Pravikrishnen Moodley⁵, Natasha Samsunder², Paul K. Drain⁶⁷⁸, Gail Hayward¹, Christopher C Butler¹, Nigel Garrett²⁹

Affiliations:
1. Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
2. Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu–Natal, Durban, South Africa.
3. eThekwini Municipality Health Unit, Durban, South Africa
4. KwaZulu-Natal Research and Innovation Sequencing Platform (KRISP), University of KwaZulu-Natal, Durban, South Africa
5. Department of Virology, University of KwaZulu-Natal and National Health Laboratory Service, Inkosi Albert Luthuli Central Hospital, KwaZulu-Natal, South Africa
6. Department of Global Health, Schools of Medicine and Public Health, University of Washington, Seattle, USA.
7. Department of Medicine, School of Medicine, University of Washington, Seattle, USA.
8. Department of Epidemiology, School of Public Health, University of Washington, Seattle, USA.
9. Discipline of Public Health Medicine, School of Nursing and Public Health, University of KwaZulu-Natal, Durban, South Africa

Corresponding Author:
Jienchi Dorward
Nuffield Department of Primary Care Health Sciences, University of Oxford,
Radcliffe Primary Care Building, Radcliffe Observatory Quarter, Woodstock Road, Oxford, OX2 6GG; Email: jienchi.dorward@phc.ox.ac.uk

Word count: 1488/1500

Keywords: HIV, viral failure, viraemia, drug resistance, dolutegravir, efavirenz.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
SUMMARY

Limited data exists to inform management of viraemia among people receiving dolutegravir-based first-line ART in low- and middle-income countries. Among South-Africans with viraemia ≥1000 copies/mL receiving dolutegravir (n=43) and efavirenz (n=37), we found no dolutegravir resistance, but high efavirenz resistance (66.7%). 12-week resuppression was higher with dolutegravir (85%) versus efavirenz (38%).
INTRODUCTION

Dolutegravir, an integrase strand transfer inhibitor (INSTI), is currently being rolled out across low and middle income countries (LMICs). It has shown better effectiveness, tolerability, and has a higher genetic barrier to drug resistance compared to previous non-nucleoside reverse transcriptase (NNRTI)-based regimens such as efavirenz. People with viraemia receiving dolutegravir may be more likely to have inconsistent adherence, than HIV drug resistance. However, the absence of widespread HIV drug resistance testing in LMICs, makes it difficult for clinicians to determine the cause of viraemia and manage it appropriately.

Among people receiving NNRTIs with viral failure (two consecutive viral loads [VLs] ≥1000 copies/mL, ≥3 months apart), approximately 70% have drug resistance, and therefore current World Health Organization (WHO) guidelines recommend switching to second-line ART. Current WHO guidelines for managing viraemia on first-line dolutegravir are less clear, because there is little data from LMICs regarding dolutegravir drug resistance and subsequent VL outcomes.

Therefore, among people with viraemia on dolutegravir and efavirenz-based first-line ART, we aimed to compare subsequent VL trajectories and drug resistance profiles.

METHODS AND ANALYSIS

We used data from the POwER study, a randomised study of point-of-care VL testing among people with HIV viraemia receiving first-line ART. The protocol and results have been previously published.

Setting and participants

POwER was conducted at two public clinics in KwaZulu-Natal, South Africa, where dolutegravir has been recommended for first- and second-line ART from December 2019. People with viraemia ≥1000 copies/mL are recommended to receive enhanced adherence counselling, with a repeat three month VL. If this remains high, those receiving efavirenz are recommended to switch to second-line ART, while those receiving dolutegravir should continue enhanced adherence counselling and repeat VL testing. Eligibility criteria for POwER were being ≥18 years old, non-pregnant, and receiving first-line dolutegravir or efavirenz-based ART, with viraemia ≥1000 copies/mL in the past six weeks and yet to receive enhanced adherence counselling. Dolutegravir recipients may have been initiated on dolutegravir, or previously transitioned from efavirenz.
Procedures

Consenting participants were enrolled, received enhanced adherence counselling, and were randomised to point-of-care or standard laboratory based VL testing after 12 weeks. Management of these VL results and clinical care during the 24 weeks of follow-up was provided by public sector healthcare workers. Plasma samples were stored at enrolment, 12 week VL and 24 week study exit visits, for retrospective VL and drug resistance testing, with results not used for clinical management. All samples with VL \( \geq 500 \text{ copies/mL} \) were sequenced using next-generation sequencing with the Illumina MiSeq platform (Illumina, San Diego, CA) (see supplementary material). We identified drug resistance mutations (DRM) at >20% frequency in protease, integrase and reverse transcriptase regions using the Stanford HIVDR database.

Variables and analyses

The main exposure was dolutegravir- or efavirenz-based ART at enrolment. We conducted descriptive analyses and used Fisher’s exact test to assess the proportions in each ART group who had viraemia \( \geq 1000 \text{ copies/mL} \) at enrolment, 12 weeks and 24 weeks. We also assessed the proportions with HIV drug resistance at each timepoint, and switched to second-line ART.

Ethical approvals

The University of KwaZulu-Natal Biomedical Research Ethics Committee (BREC 00000836/2019) and the University of Oxford Tropical Research Ethics Committee (OxTREC 66-19) approved the study.

RESULTS

Participants

We enrolled 80 eligible participants between August- March 2022. Median age was 38.5 years (interquartile range [IQR] 33-45), 58.8% were female, and median time on ART was 3.2 years (IQR 1.0-6.0) (Table S1).

At enrolment, 37 (46.3%) had been receiving efavirenz-based first-line regimens for a median of 3.2 years (1.1-5.0), and 43 (53.7%) had been receiving dolutegravir for a median of 0.7 years (IQR 0.5-1.1). 15/43 (34.9%) had been initiated on dolutegravir, while the other 28/43 (65.1%) had been initiated on an efavirenz-based regimen and were subsequently transitioned to first-line dolutegravir. The dolutegravir group had less time on ART, slightly higher incomes and
higher CD4 counts, but otherwise were similar to the efavirenz group (Table S1). All participants were receiving tenofovir disoproxil fumarate, apart from one dolutegravir participant receiving abacavir.

**Viraemia and HIV drug resistance**

**Enrolment**

The median time since the pre-enrolment VL of ≥1000 copies/mL to enrolment was around two weeks (Table 1). At enrolment, the numbers with viraemia ≥1000 copies/mL had fallen to 18/43 (41.9%) dolutegravir participants, compared to 27/37 (73.0%) efavirenz participants (p=0.007).

Of the 50 participants with VLs >500 copies/mL, HIVDR testing was successful in 48 for reverse transcriptase and 47 for integrase. The proportion with DRMs against either of the nucleoside reverse transcriptase inhibitor (NRTI) backbone drugs was lower in dolutegravir participants (2/19, 10.5%, 95% CI 1.9, 32.9) compared to efavirenz participants (21/29, 72.4%, 54.0, 85.4, p=<0.001, Table 1). In efavirenz participants, 25/29 (86.2%, 68.7, 95.0) had DRMs against efavirenz, while among dolutegravir participants there were no DRMs against dolutegravir.

**Follow-up**

By the time of the 12-week VL, participants in both the dolutegravir and efavirenz group had a median of 1 (IQR 1, 1) enhanced adherence counselling sessions. Only 6/43 (15.0%) of dolutegravir participants had a VL ≥1000 copies/mL and were classified as having viral failure, compared to 23/37 (62.2%) efavirenz participants (p<0.001). Of the 27/32 with VL >500 copies/mL and successful HIVDR testing, none of the dolutegravir participants had dolutegravir or NRTI DRMs, compared to 19/21 (90.5%, 69.6, 98.4) efavirenz participants who had resistance against the NRTI backbone (p<0.001). 21/21 (100%, 81.4, 100) had resistance against efavirenz. All 23 efavirenz participants with confirmed viral failure at 12 weeks, and one other with a repeat VL of 937 copies/mL, were switched to second-line regimens (Tables 1 and S2), at a median of 90 days (IQR 84, 99) weeks after enrolment. The commonest second line regimen was zidovudine, lamivudine and dolutegravir.

At the 24-week exit visit, two participants in each group were lost to follow-up, and one dolutegravir participant had no exit viral load taken. Of those with exit viral loads, viraemia was detected in 6/40 (15.0%) of those who were receiving dolutegravir at enrolment, versus 2/35 (5.7%) of those who were receiving efavirenz at enrolment (p=0.271). Among the 8/10 with successful NRTI HIVDR testing, 1/5 (20.0%, 2.5, 64.1) in the dolutegravir enrolment group had resistance against the NRTI backbone versus 3/3 (100%, 40.0, 100) in the efavirenz enrolment.
group. One participant who was receiving TLD from enrolment, and had only NNRTI DRMs at enrolment, developed an emergent K65R mutation by week 24 (Table S2). There were no dolutegravir DRMs detected from enrolment to study exit in any participants.

**DISCUSSION**

At enrolment and 12-week follow-up, people receiving efavirenz-based ART with viraemia had high levels of DRMs against their first-line regimen, while people receiving dolutegravir had minimal resistance. Consequently dolutegravir participants had higher levels of resuppression at 12-weeks compared to efavirenz. After switching to second-line ART, 24-week viral resuppression in efavirenz participants became similar to dolutegravir, with few DRMs in both groups.

Among participants receiving dolutegravir-based ART at baseline, there were no INSTI mutations, meaning that viraemia was likely caused by poor adherence. Our study is one of the first to report outcomes among people experiencing viraemia on first-line dolutegravir in LMICs, with 85.0% achieving viral suppression <1000 copies/mL after 12 weeks. In contrast, a high proportion of participants receiving efavirenz-based ART had baseline NRTI and NNRTI resistance, meaning resistance was contributing to viraemia. After 12 weeks, 37.8% resuppressed to <1000 copies/mL, similar to the 46.4% among people receiving NNRTI-based ART in a large systematic review. The remaining participants only resuppressed after switching to second-line ART. One other study compares resuppression among people with viraemia receiving dolutegravir versus efavirenz in LMICs. Among people with viraemia after initiating ART in the ADVANCE trial, resuppression was more frequent in the dolutegravir group (155/247, 62.8%) compared to efavirenz (44/138, 32%, p <0.001). There was one case of emergent resistance to dolutegravir.

Strengths of our study include the focus on people with viraemia while receiving dolutegravir, successful HIVDR testing in a high proportion of those with viraemia, and frequent VL testing. The small sample size meant we could not adjust for potential confounding factors that could contribute the difference in outcomes between dolutegravir and efavirenz participants. For example, people who were transitioned to dolutegravir may be better engaged in care or motivated to adhere to treatment, and therefore also more likely to resuppress. Follow-up time was short, and the median time on dolutegravir was less than a year.

Nevertheless, our findings, alongside those of the ADVANCE study, demonstrate that early in the South African rollout, viraemia among people receiving dolutegravir is largely due to poor adherence.
adherence, rather than drug resistance. This supports the current South African and WHO
guidelines, which do not recommend early switching to second-line ART among people
receiving dolutegravir with viraemia. The high cost of HIV drug resistance testing, and low
prevalence of drug resistance, mean that South African Guidelines only recommend drug
resistance after two years of viraemia. Further evidence is needed to determine the extent and
impact of emergent DRMs with longer term viraemia on dolutegravir. In the meantime,
managing viraemia among people receiving dolutegravir should have a renewed focus on
interventions to support adherence, rather than managing HIVDR.

LIST OF ABBREVIATIONS

ART – antiretroviral therapy
PLHIV – people living with HIV
LMIC – low- and middle-income countries
UNAIDS - Joint United Nations Programme on HIV/AIDS
WHO – World Health Organization

DECLARATIONS

Competing interests
Cepheid provided point-of-care VL assays at no cost for use at the study site. The authors have
no other competing interests to declare.

Funding
This work is supported by grants from the Wellcome Trust PhD Programme for Primary Care
Clinicians (216421/Z/19/Z), the University of Oxford’s Research England QR Global Challenges
Research Fund (0007365) and the Africa Oxford Initiative (AfiOx-119). HIV drug resistance
testing and drug concentration testing was funded by the National Institute for Health and Care
Research (NIHR) Community Healthcare MedTech and In Vitro Diagnostics Co-operative at
Oxford Health NHS Foundation Trust (MIC-2016-018); GH, CCB & PJT also receive funding
from this award. The views expressed are those of the author(s) and not necessarily those of
the NHS, the NIHR or the Department of Health and Social Care. For the purpose of open
access, the author has applied a CC BY public copyright licence to any Author Accepted
Manuscript version arising from this submission. The University of Oxford is the study sponsor.
The funders and sponsor had no role in study design, manuscript submission, or collection,
management, analysis or interpretation of study data.
Author contributions
JD and NG conceived the study. YS, RL, EB, PM, NS, PKD, GH and CB contributed to study design and implementation. JD analysed the data and wrote the first draft of the manuscript. All authors critically reviewed and edited the manuscript and consented to final publication.

Acknowledgements
The authors would like to thank all participants in the study and acknowledge the work and support of staff at the Prince Cyril Zulu Clinic, Mafakathini Clinic, eThekwini Municipality, CAPRISA and the National Health Laboratory Services at Addington and Inkosi Albert Luthuli Hospitals.

Data sharing statement
Bona fide researchers will be able to request access to anonymised trial data by contacting the corresponding author.
REFERENCES


### Table 1: Outcomes among patients with viraemia on dolutegravir and efavirenz based first-line ART

<table>
<thead>
<tr>
<th>Variable</th>
<th>Levels</th>
<th>Dolutegravir, n = 43</th>
<th>Efavirenz, n = 37*</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ENROLMENT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Days since pre-enrolment viral load ≥1000 copies/mL</td>
<td>Median (IQR)</td>
<td>16.0 (13.5 to 20.0)</td>
<td>14.0 (13.0 to 21.0)</td>
<td>0.333</td>
</tr>
<tr>
<td>Enrolment viral load, copies/mL</td>
<td>&lt;1000 copies/mL</td>
<td>25 (58.1)</td>
<td>10 (27.0)</td>
<td>0.007</td>
</tr>
<tr>
<td></td>
<td>≥1000 copies/mL</td>
<td>18 (41.9)</td>
<td>27 (73.0)</td>
<td></td>
</tr>
<tr>
<td>Predicted active NRTIs in current regimen†</td>
<td>0</td>
<td>1 (5.3)</td>
<td>12 (41.4)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>1 (5.3)</td>
<td>9 (31.0)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>17 (41.9)</td>
<td>8 (28.6)</td>
<td></td>
</tr>
<tr>
<td>Predicted active dolutegravir or efavirenz in current regimen†</td>
<td>No</td>
<td>0 (0.0)</td>
<td>25 (86.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>18 (100.0)</td>
<td>4 (13.8)</td>
<td></td>
</tr>
<tr>
<td><strong>WEEK 12 FOLLOW-UP</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time to follow-up viral load, days</td>
<td>Median (IQR)</td>
<td>91.0 (84.0 to 98.0)</td>
<td>90.5 (84.0 to 98.0)</td>
<td>0.613</td>
</tr>
<tr>
<td>Follow-up viral load, copies/mL‡</td>
<td>&lt;1000 copies/mL</td>
<td>34 (85.0)</td>
<td>14 (37.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>≥1000 copies/mL</td>
<td>6 (15.0)</td>
<td>23 (62.2)</td>
<td></td>
</tr>
<tr>
<td>Predicted active NRTIs in current regimen§</td>
<td>0</td>
<td>0 (0.0)</td>
<td>13 (41.9)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>0 (0.0)</td>
<td>6 (28.6)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>6 (100.0)</td>
<td>2 (9.5)</td>
<td></td>
</tr>
<tr>
<td>Predicted active dolutegravir or efavirenz in current regimen§</td>
<td>No</td>
<td>0 (0.0)</td>
<td>21 (100.0)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>6 (100.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>ART regimen change during follow-up?</td>
<td>No</td>
<td>43 (100.0)</td>
<td>6 (16.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>31 (83.8)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reason for ART regimen change</td>
<td>ART policy change</td>
<td>7 (22.6)</td>
<td></td>
<td>1.000</td>
</tr>
<tr>
<td></td>
<td>Virological failure</td>
<td>24 (77.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>New ART regimen</td>
<td>AZT / 3TC / DTG</td>
<td>17 (54.8)</td>
<td></td>
<td>1.000</td>
</tr>
<tr>
<td></td>
<td>AZT / 3TC / LPVr</td>
<td>2 (6.5)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TDF / 3TC / DTG</td>
<td>7 (22.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TDF / AZT / 3TC / DTG††</td>
<td>4 (12.9)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TDF / FTC / LPVr</td>
<td>1 (3.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>WEEK 24 EXIT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exit viral load, copies/mL**</td>
<td>&lt;1000 copies/mL</td>
<td>34 (85.0)</td>
<td>33 (94.3)</td>
<td>0.271</td>
</tr>
<tr>
<td></td>
<td>≥1000 copies/mL</td>
<td>6 (15.0)</td>
<td>2 (5.7)</td>
<td></td>
</tr>
<tr>
<td>Predicted active NRTIs in current regimen††</td>
<td>0</td>
<td>1 (20.0)</td>
<td>2 (66.7)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>0 (0.0)</td>
<td>1 (33.3)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>4 (80.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td>Predicted active dolutegravir or efavirenz in current regimen††</td>
<td>No</td>
<td>0 (0.0)</td>
<td>0 (0.0)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Yes</td>
<td>7 (100.0)</td>
<td>3 (100.0)</td>
<td></td>
</tr>
</tbody>
</table>

* One participant had been transitioned from TDF / FTC / EFV to TDF / 3TC / DTG 15 days before enrolment, on the same day of the pre-enrolment viral load. At the enrolment visit, they were changed back to TDF / FTC / EFV because they should not have been transitioned while viraemic >1000 copies/mL. Their 12-week follow-up viral load was 1222 copies/mL, and so they were switched from TDF/FTC/EFV to second-line AZT/3TC/LPVr.
† 50 participants had viral load >500 copies/mL and HIVDR testing was successful in 48 for reverse transcriptase and
47 for integrase.
‡ Three participants in the dolutegravir group had no follow-up viral load.
§ 32 participants had viral load >500 copies/mL and HIVDR testing was successful in 27 for both reverse transcriptase and integrase.
One participant with repeat viral load of 937 copies/mL was deemed by the clinician to have virological failure and
switched to second line AZT/3TC/DTG.
¶ Remained on tenofovir due to Hepatitis B infection.
** Two participants in each group were lost to follow-up, and one dolutegravir participant had no exit viral load.
†† 10 participants had viral load >500 copies/mL and HIVDR testing was successful in 8 for reverse transcriptase and 10 for integrase.